Scribd
Upload
84 views2 pages

Tnkhetp LBL

Tenecteplase is recommended by guidelines as the preferred thrombolytic drug over others for STEMI patients. It is easy to prepare and administer via a 5 second IV push, less costly than alternatives. When used with thrombolytics for STEMI, enoxaparin administered via initial IV bolus followed by twice daily subcutaneous injections for about a week is considered an effective anticoagulant treatment that allows for early patient mobilization.

Uploaded by

vijayabhavani.s
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
84 views2 pages

Tnkhetp LBL

Tenecteplase is recommended by guidelines as the preferred thrombolytic drug over others for STEMI patients. It is easy to prepare and administer via a 5 second IV push, less costly than alternatives. When used with thrombolytics for STEMI, enoxaparin administered via initial IV bolus followed by twice daily subcutaneous injections for about a week is considered an effective anticoagulant treatment that allows for early patient mobilization.

Uploaded by

vijayabhavani.s
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

In STEMI patients,

TNKPLASE 40
Tenecteplase Lyophilized powder for Injection 40 mg
A single-bolus thrombolytic, approved by the USFDA for use in mortality
reduction associated with Acute Myocardial Infarction (AMI).

ACC & AHA and other guidelines recommend Tenecteplase to be chosen


as the most preferred drug of choice over any other thrombolytic.

Easier to prepare, easier to administer, less costly & IV push


over 5 seconds.

TNKPLASE is biosimilar thrombolytic product developed at Hetero USFDA


approved manufacturing facility.
TNKPLASE 40

Tenecteplase
In Lyophilized powder for Injection 40 mg
TNKPLASE 40

Myocardial Infarction TNKPLASE 40

TNK tissue Plasminogen Activator


Lyophilized Powder for Intravenous Injection

Acute Ischemic Stroke Single use Vial

Powder and Sterile Water for Injections I.P. (SWFI / Diluent)


Please follow accurately the instruction for use.
Failure to do so may lead to greater than the required
dose of Tenecteplase being administered.

Pulmonary Embolism 1 Vial of Tenecteplase Lyophilized powder for Injection


1 Vial of Sterile Water for Injections I.P.
1 Sterile Syringe with 21 gauge needle

No need for cold storage

Ref: * Tenecteplase Kieu-Tram Bach; Forshing Lui.June 25, 2023.


THE GOLD STANDARD IN CLOT THERAPY

HETPARIN
Enoxaparin Sodium 40 mg and 60 mg Injection

Initial intravenous bolus of enoxaparin followed by twice daily subcutaneous


administration for about 1 week should be considered for the treatment of
patients with STEMI receiving thrombolysis.

Along with its easiness of use, not requiring laboratory monitoring, the
subcutaneous administration of enoxaparin allows extended antithrombotic
treatment, while permitting early mobilization (and rehabilitation) of patients.

In patients with ST-elevation acute myocardial infarction (STEMI) undergoing


thrombolytic treatment with ibrin-speci ic agents (such as alteplase, reteplase,
and tenecteplase), concurrent anticoagulation is warranted, in order to improve
early recanalization and reduce reocclusion and reinfarction rates.

In
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)

HETPARIN 40
HETPARIN 60
HETPARIN 40

HETPARIN 60

Low Molecular Weight Heparin Low Molecular Weight Heparin


Enoxaparin Sodium Injection IP 40mg / 0.4mL Enoxaparin Sodium Injection IP 60mg / 0.6mL
For Subcutaneous use only For Subcutaneous use only
HETPARIN 40 1 Pre - Filled Syringe HETPARIN 60 1 Pre - Filled Syringe
Single dose Syringe Single dose Syringe

Ref: Vasc Health Risk Manag. 2007 Oct; 3(5): 691–700.

You might also like